treatment passport 1

Similar documents
HIV Drugs and the HIV Lifecycle

Antiretroviral Dosing in Renal Impairment

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

ANTIRETROVIRAL TREATMENTS (Part 1of

Selecting an Initial Antiretroviral Therapy (ART) Regimen

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Approach for the Newly Diagnosed HIV Positive Patient

Exploring HIV in 2017: What a pharmacist needs to know

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

ABRIDGED ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

Simplifying HIV Treatment Now and in the Future

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

HIV Clinical Nurse Specialist CCDHB Wellington

The ART of Managing Drug-Drug Interactions in Patients with HIV

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

Antiretrovial Crushable/Liquid Formulation Chart

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

HIV medications HIV medication and schedule plan

Comprehensive Guideline Summary

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Matters of the HAART: An Update on Current Treatment Options for HIV

Jonathan Cohn MD Wayne State University July 24,

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

HIV Treatment Guidelines

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Fundamentals of Antiretroviral Therapy

HIV Management Update 2015

Nothing to disclose.

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

Didactic Series. Switching Regimens in the Setting of Virologic Suppression

A Changing Landscape: New and Pipeline HIV Therapies

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

Nobel /03/28. HIV virus and infected CD4+ T cells

SELECTING THE BEST ART FOR EACH PATIENT

ART and Prevention: What do we know?

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options


HIV Treatment: New and Veteran Drugs Classes

30 Years of HIV: An Update on Treatment Guidelines and Beyond

Pharmacological considerations on the use of ARVs in pregnancy

The ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners

Guide to changing ART:

TRANSPARENCY COMMITTEE

Antiretroviral Drugs

Midwestern Underwriting Conference 2016

Medication Errors Focus on the HIV-Infected Patient

Sculpting a Better Regimen: The ART of HIV Medications

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

Starting Immediate Treatment for HIV-1

Treatment update 2017: new drugs, cure and PrEP. Simon Collins HIV i-base

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

Addressing Pediatric Needs of the Most Neglected: next steps

HIV Infection & AIDS in Low- and Middle-Income Countries

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters

What's new in the WHO ART guidelines How did markets react?

HIV/AIDS Prenatal Care for HIV+ Mothers. 1. Algorithm for Prenatal Screening & Care (Antepartum)

Criteria for Oral PrEP

MEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP

Human Immunodeficiency Virus (HIV)

Appropriate Use & Safety Edits

Eviplera: New First-Line Treatment Options for patients with HIV (own clinical experience in Izrael) Itsik Levy MD

Starting Immediate Treatment for HIV-1

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

Overview of HIV. LTC Paige Waterman

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

Disclosures. Goals. US DHHS Guidelines: 1 st Line Therapy. Antiretroviral Therapy Initiation:

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

Paediatric antiretroviral therapy.

Drug Treatment Program Update

Susan L. Koletar, MD

Antiretroviral Pregnancy Registry

October 26-28: Training Day 1

HIV / AIDS & Opportunistic Infections.

Antiretroviral Therapy

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

HIV for the Non-ID Pharmacist

treatment VIRAL SUPPRESSION SUPPORT ART IS THE ONLY WAY TO CONTROL HIV TIPS FOR TAKING ART ADHERENCE Benefits of ART Start Know Your ARVs today ARVs

ART: The New, The Old and The Ugly

Guide to changing treatment:

Continuing Education for Pharmacy Technicians

Updated Guidelines for Managing HIV/HCV Co-Infection

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

HIV - Therapy Principles

Transcription:

treatment passport 1

Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor changes at your clinic. It can help if you speak to other healthcare workers or to a treatment phoneline for advice. It can help if you ever change hospitals or clinics. Or if you want a second opinion, when on holiday or abroad. Or if you move to another country. Any treatment choice in the future is closely linked to your previous treatment history. This history includes results from CD4, viral load and resistance tests. It also includes the drugs you have used and your reasons for changing them. As treatment improves you could need this record for 20 years or more - and whether new drug work may depend on previous treatment. This record is important if you change clinic. You should ask for your medical records to be forwarded, but this does not always happen. Make sure that you have a record of your GUM or clinic number. This book will be useful in all these situations. Please bring it when you visit your clinic. Your doctor can provide you with details to help fill in this book but it does not replace your medical notes. All patients have the right to see their medical records and to make photocopies from them. i-base can provide additional books or pages if you need them - please call 020 8616 2210. 2

Name: Date of birth: Known allergies ie penicillin, Septrin etc - see also page14. Allergies: Current hospitals or clinics Name Patient no. Phone no. Name Patient no. Phone no. Name Patient no. Phone no. Other useful phone numbers or email addresses: Pharmacy GP i-base treatment information phoneline: i-base run a confidential free treatment information phoneline on Monday, Tuesday and Wednesday from 12-4pm: 0808 800 6013 If found please return to: OR post to the confidential i-base return service: i-base, 107 The Maltings, 169 Tower Bridge Rd, London SE1 3LJ 3

Hospitals and clinics Keep a record of the hospitals and clinics where you have been treated. This can include specialist clinics as well as your main hospital. Date of diagnosis: Date of seroconversion: (if known) Hospital name Main doctors seen Dates First seen: Left: Contact details: First seen: Left: Contact details: First seen: Left: Contact details: 4

Hospital name Main doctors seen Dates First seen: Left: Contact details: First seen: Left: Contact details: First seen: Left: Contact details: First seen: Left: Contact details: First seen: Left: Contact details: 5

CD4 and viral load The CD4 and viral load are the main blood tests to monitor your health and your response to treatment. CD4 count - This blood test checks your immune system CD4% - This is similar to the CD4 count but is often more stable Viral load - This test measures the amount of HIV in a sample of blood. It is used to decide when you need to start treatment, and whether the treatment is working effectively. In your previous history, even rough figures are useful. Your doctor can provide these. The lowest ever CD4 count and highest ever viral load and results are the most important. This is from when you were first diagnosed and before you start, stop or changed treatment. Date CD4 CD4% Viral load (month / year) (cells/mm3) e.g july 04 234 14 80,000 6

Date CD4 CD4% Viral load (month / year) (cells/mm3) 7

Date CD4 CD4% Viral load (month / year) (cells/mm3) 8

Other tests Keep a record of resistance and other tests. Note that resistance test results are very detailed and complicated - but also very important in deciding treatment. Ask for a full copy of these results and keep them safely. Date Test name Main resullts (month/year) e.g july 2014 genotype 3TC resistance (M184V) 9

Antretroviral treatment history Your choice of new and future drugs will depend on the drugs you have used in the past. It also depends on the reason you stopped using them. This is mainly because of resistance and side effects. If you don;t have exact details, even rough dates are useful (ie taking efavirenz for 3 months in 2014). A list of drug names is included on page 19. Drugs & combination details (name +dose) Date started Date stopped Reason e.g efavirenz 600mg Feb 2014 May 2014 bad sleep and dreams 10

Drugs & combination details (name +dose) Date started Date stopped Reason 11

Drugs & combination details (name +dose) Date started Date stopped Reason 12

VIRAL LOAD SCALE 1200 1100 1000 800 700 600 500 400 300 200 150 100 50 Some people like to plot results on a graph - use one colour for viral load and another for CD4. Note that the scales are not constant at highest and lowest ranges. DATE (month / year) >1 million 1,000,000 500,000 300,000 200,000 100,000 50,000 30,000 10,000 5,000 1,000 <500 <50 13 CD4 COUNT

Side effect and allergies Please list main side effects or drug-related allergies. Side effect or symptom Suspected drug Date started/ stopped 14

Other infections and illnesses A record of other infections (eg TB) or HIV-related illnesses (CMV, PCP, shingles etc) is important. Illness or infection Treatment + dose Dates 15

Hepatitis Co-infection with hepatitis A, B or C can make treating HIV more complicated. Your hospital should test you for these when you are first diagnosed, and offer you vaccinations against hepatitis A and B if you are not already protected (see page 16). You should be tested every year for hepatitis C. Hepatitis Test date Treatment if any + dates genotype 16

Immunisation record A record of vaccination and immunisation (hepatitis A and B, pneumovax, flu, tetanus and holiday vaccinations etc) can also help. HIV positive people usually require non-live vaccinations. You may have to ask for these specially. Vaccination or immunisation Date 17

Trials and studies Include a record of any studies or trial medications that you have used. Study name and treatment received Dates 18

Names of commonly used meds Most drugs are known by several names including a chemical name, a brand name and an abbreviated name. The most common names for drugs available when this booklet was printed are listed below with space to add new drugs as they are approved. Chemical Trade Abb. Integrase Inhibitors: (INIs or INSTIs) dolutegravir Tivicay DOL elvitegravir Vitetka EVG raltegravir Isentress RAL NNRTIs: ( non-nukes ) efavirenz Sustiva EFV nevirapine Viramune NVP etravirine Intelence ETR rilpivirine Edurant RPV NRTIs: ( nukes ) and dual-nukes Kivexa (ABC+3TC) KVX Truvada (TDF+FTC) TVD Descovy (TAF+FTC) F/TAF emtricitabine Emtriva FTC lamivudine Epivir 3TC abacavir Ziagen ABC tenofovir DF Viread TDF tenofovir AF TAF Protease Inhibitors: (PIs) atavanavir Reyataz ATZ darunavir Prezista DRV tipranavir Aptivus TPV Entry Inhibitors: enfuvirtide Fuzeon T-20 maraviroc Celsentri MVC Chemical Trade Abb. Fixed Dose Combinations (FDCs) Atripla (EFV+TDF+FTC) Eviplera (RPV+TDF+FTC) Genvoya (EVG/c+FTC+ TAF) Odefsey (RPV+TAF+FTC) Stribild (EVG/c + FTC+TDF) Triumeq (DOL+ABC+3TC) Trizivir (AZT+3TC+ ABC) Booster drugs (/r or /c) ritonavir Norvir RTV or /r cobicistat COB or /c Booster dual formulations (/r or /c) Evotaz (atazanavir/c) Rezolsta (darunavir/c) Kaletra (lopinavir/r) Drugs for related infections: Septrin cotrimoxazole Acyclovir Zovirax foscarnet Foscavir interferon various INF ribavirin various RBV 19

Produced by i-base and the Royal Free Hospital. i-base is a registered charity no1081905. Tel: 020 8616 2210 admin@i-base.org.uk www.i-base.info December 2016 20